• The importance of FXR FGF signaling in BA

  2022-06-13

  

  The importance of FXR-FGF15/19 signaling in BA homeostasis is illustrated by various BA malabsorption syndromes. Clinically, BA malabsorption causes diarrhea due to high BA concentrations in the colon that lead to secretion of water and electrolytes and stimulation of propulsive contractions [36]. P

• GnRH ant have been designed to obtain pharmacological compou

  2022-06-13

  

  GnRH-ant have been designed to obtain pharmacological compounds to block the pituitary–gonadal axis without the undesirable flare effect exerted by GnRH itself or by the GnRH-a (see Section 2.2). GnRH-ant competitively block the binding of GnRH to GnRHRs (Schally, 1999; Tan & Bukulmez, 2011); they p

• Ironically another series of studies examining the

  2022-06-13

  

  Ironically, another series of studies examining the role of EAATs in CNS injury and disease suggest that under some pathological conditions, the operation of the EAATs is not protective, but actually contributes to the excitotoxic process (Rossi et al., 2000). The transporters do so by serving as th

• In respect of clinical development Takeda

  2022-06-13

  

  In respect of clinical development Takeda has pioneered the field with the GPR40 agonist TAK-875 or fasiglifam (Figure 2A), which in phase-II studies decreased HbA1c as efficiently as sulfonylurea without signs of hypoglycemia [24]. This was obtained with surprisingly little effect on systemic insul

• br Experimental methods br Acknowledgments We thank all memb

  2022-06-13

  

  Experimental methods Acknowledgments We thank all members of the Hermanson lab, especially Ana Teixeira, Shirin Ilkhanizadeh and Karolina Wallenborg, for assistance and discussions, Peter Löw for anti-synaptotagmin antibody, and Lars Björklund, Ole Isacson, Christer Höög, Claes Wahlestedt and

• The expression of GLUT receptors throughout

  2022-06-13

  

  The expression of GLUT receptors throughout the body could be considered a potential source for off-target effects even for engineered glucose-conjugated nanomedicines, as there are at least 12 types of GLUT transporters in the body, including GLUT1 in erythrocytes and the blood-brain barrier, as we

• br Acknowledgements This work was supported by the National

  2022-06-13

  

  Acknowledgements This work was supported by the National Institutes of Health [grant number GM024417]. Introduction In mammals, glucose is the major energy substrate supporting conceptus development after DMAP formation [1,2]. While the equine morula uses similar amounts of pyruvate and gluc

• br GLP R expression in the

  2022-06-13

  

  GLP-1R expression in the vascular endothelium Immunohistochemistry studies utilizing GLP-1R antibodies that have now been demonstrated to be non-specific [46], initially identified GLP-1R protein expression in both mouse mesenteric artery SMCs and heart coronary SMCs [7]. However, evidence for VS

• Olanzapine has been reported to attenuate insulin secretion

  2022-06-13

  

  Olanzapine has been reported to attenuate insulin secretion, cause insulin resistance (Chintoh et al., 2008) and reduce whole body carbohydrate oxidation (Klingerman et al., 2014). However, a blunting of these effects in Gcgr−/− mice would not appear to explain the protection against olanzapine-indu

• br Introduction The glucagon receptor GCGR is a G protein

  2022-06-13

  

  Introduction The glucagon receptor (GCGR) is a G-protein-coupled receptor expressed mainly in the liver and kidney. Upon glucagon binding, it activates the stimulatory G protein (Gs) and increases cAMP level, subsequently transducing glucagon signaling involved in glucose, amino acids and lipid m

• The gene structures of cGalR and cGalR L were

  2022-06-10

  

  The gene structures of cGalR2 and cGalR2-L were determined by in silico comparison with the chicken genomic DNA sequences retrieved from the Ensembl database. Both cGalR2 and cGalR2-L genes are composed of two coding exons, separated by single introns of 0.9kb (cGalR2) or 3kb (cGalR2-L) locating wit

• Since our new compound Fex could be a new FXR

  2022-06-10

  

  Since our new compound Fex-3 could be a new FXR ligand, we try to demonstrate that Fex-3 was an intestinal-restricted FXR agonist which only activated FXR in the intestine not in the liver or other organs. Initially, we investigated this in Caco-2 luteolin with transwell experiments. From and , we

• Some malignant human tumors cells also express FPRs and

  2022-06-10

  

  Some malignant human tumors could also express FPRs and respond to bacterial or endogenous agonists by increased motility and growth. For instance, FPRs expressed by human gastric cancer cells, mediate epithelial–mesenchymal transition, cell proliferation, migration, and resistance to apoptosis [30

• In addition we assessed the

  2022-06-10

  

  In addition, we assessed the viability of 1,2,3,4-tetrahydroquinoline (13t) and 1,2,3,4-tetrahydroisoquinoline (13u) as the tail on account of our previous SAR results. To our delight, 13t and 13u each had comparable activity to that of 13c, with 13u being slightly more potent than 13c. Further stru

• Through experimental models and clinical experiments those f

  2022-06-10

  

  Through experimental models and clinical experiments, those four drugs above can shown efficacy-enhancing and toxicity-reducing effects after compatibility. Our preclinical studies showed that XFC has a definite effect on relieving joint symptoms in RA patients. XFC can improve joint pain, swelling,

15996 records 416/1067 page Previous Next First page 上5页 416417418419420 下5页 Last page